v3.26.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Jun. 30, 2025
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Annual Report true  
Document Transition Report false  
Document Period End Date Dec. 31, 2025  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus FY  
Entity File Number 001-42490  
Entity Registrant Name MAZE THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-2635018  
Entity Central Index Key 0001842295  
Entity Address, Address Line One 171 Oyster Point Blvd.  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town South San Francisco  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94080  
City Area Code 650  
Local Phone Number 850-5070  
Title of 12(b) Security Common Stock - par value $0.001 per share  
Trading Symbol MAZE  
Security Exchange Name NASDAQ  
Entity Well-known Seasoned Issuer Yes  
Entity Voluntary Filers No  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
ICFR Auditor Attestation Flag false  
Document Financial Statement Error Correction [Flag] false  
Documents Incorporated by Reference

Portions of the registrant’s Definitive Proxy Statement relating to its 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2025.

  
Entity Public Float   $ 443.9
Auditor Firm ID 42  
Auditor Name Ernst & Young LLP  
Auditor Location San Mateo, California  
Auditor Opinion [Text Block]

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Maze Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive (loss) income, redeemable convertible preferred stock and stockholders’ equity (deficit) and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.